Trial reportPloS one2012
Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00565318 (A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.BMJ open · 2022Pooled it
- Inflammatory Activities in Type 2 Diabetes Patients With Co-morbid Angiopathies and Exploring Beneficial Interventions: A Systematic Review.Frontiers in public health · 2020Pooled it
- Advanced Glycation End Products in Disease Development and Potential Interventions.Antioxidants (Basel, Switzerland) · 2025Review
- Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes.Frontiers in pharmacology · 2025Article
- Natural product-based treatment potential for type 2 diabetes mellitus and cardiovascular disease.World journal of diabetes · 2024Article
- Thiamine deficiency in diabetes, obesity and bariatric surgery: Recipes for diabetic ketoacidosis.Journal of family medicine and primary care · 2024Review
- Article
- Review
- The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy.Annals of medicine · 2023Article
- Effects of Chicken Serum Metabolite Treatment on the Blood Glucose Control and Inflammatory Response in Streptozotocin-Induced Type 2 Diabetes Mellitus Rats.International journal of molecular sciences · 2022Article
- Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease.Frontiers in medicine · 2022Article
- The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review.Molecular medicine (Cambridge, Mass.) · 2018Review
- Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies.Nutrition & metabolism · 2018Review
- Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.PloS one · 2018Article
- Targeting advanced glycation with pharmaceutical agents: where are we now?Glycoconjugate journal · 2016Review
- Article
- Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease.Research in cardiovascular medicine · 2015Review
- Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells.PloS one · 2015Article
- Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation?World journal of diabetes · 2014 · on this mapReview
- Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse.The Journal of physiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFormation of advanced glycation endproducts (AGEs), endothelial dysfunction, and low-grade inflammation are intermediate pathways of hyperglycemia-induced vascular complications. We investigated the effect of benfotiamine on markers of these pathways in patients with type 2 diabetes and nephropathy.
methodsPatients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43). Plasma and urinary AGEs (N(ε)-(carboxymethyl) lysine [CML], N(ε)-(Carboxyethyl) lysine [CEL], and 5-hydro-5-methylimidazolone [MG-H1]) and plasma markers of endothelial dysfunction (soluble vascular cell adhesion molecule-1 [sVCAM-1], soluble intercellular adhesion molecule-1 [sICAM-1], soluble E-selectin) and low-grade inflammation (high-sensitivity C-reactive protein [hs-CRP], serum amyloid-A [SAA], myeloperoxidase [MPO]) were measured at baseline and after 6 and 12 weeks.
resultsCompared to placebo, benfotiamine did not result in significant reductions in plasma or urinary AGEs or plasma markers of endothelial dysfunction and low-grade inflammation.
conclusionsBenfotiamine for 12 weeks did not significantly affect intermediate pathways of hyperglycemia-induced vascular complications. TRIAL REGRISTRATION: ClinicalTrials.gov NCT00565318.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.